BD reports Q2 increase in revenues

By LabPulse.com staff writers

May 6, 2022 -- Becton Dickinson (BD) reported an increase in revenues for the second quarter of 2022, despite continuing to experience a decline in revenue worldwide from COVID-19 testing.

The company reported revenues of $5 billion in the second quarter (end-March 31, 2022), an increase of 2.1% over the same time period last year. The increase was driven by base revenue growth of 8.2%, partially offset by a decline in worldwide COVID-only testing revenues to $214 million from $474 million in the same period last year, BD said.

The company posted net income of $454 million, compared to net income of $299 million in the second quarter of fiscal year 2021.

BD reports revenue declines for Q1
Becton Dickinson (BD) recently reported declines in revenue for the first quarter of the 2022 fiscal year, with its Life Sciences segment experiencing...
BD buys flow cytometry technology firm Cytognos
Becton Dickinson (BD) has acquired flow cytometry technology developer Cytognos from Spanish firm Vitro. Cytogen's technology is used to diagnose blood...
BD Cor system features MX instrument for infectious diseases
Becton Dickinson (BD) recently expanded its BD Cor system to include a new MX instrument for molecular testing of infectious diseases.
Qiagen and BD settle PCR patent lawsuit
Qiagen and Becton Dickinson (BD) have reached a settlement in a patent infringement lawsuit involving polymerase chain reaction (PCR) tests that Qiagen...
BD launches new BD Cor molecular diagnostics system
Becton Dickinson (BD) has launched a robotics-based, high-throughput molecular diagnostic system called BD Cor that will be available to labs in the U.S....

Copyright © 2022 LabPulse.com

Last Updated mp 5/6/2022 8:06:53 AM